brevifolincarboxylic acid

Brevifolincarboxylic acid (BA) is a natural polyphenol and a metabolite derived from the gut microbiota. It has been identified as a potential therapeutic agent for the prevention and treatment of drug-induced liver injury (DILI), particularly that caused by third-generation EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib. Research indicates that BA levels are significantly downregulated in patients experiencing DILI. Mechanistically, BA exerts hepatoprotective effects by inhibiting the activation of the TLR4/MyD88/NF-κB signaling pathway, which in turn reduces the release of pro-inflammatory cytokines like IL-6, IL-1β, and TNF-α, and prevents hepatocyte apoptosis. Preclinical studies in mouse models and in vitro assays have demonstrated its ability to reverse hepatocyte toxicity and alleviate liver tissue inflammatory damage.

Other names

brevifolin carboxylic acid